Segmentation by types of parasitic infection testing differentiates the market into five methodological families, each influencing overall size through distinct cost structures and adoption rates. Microscopy‑based techniques, including wet‑mount and concentration methods, retain a 20 % share due to low‑cost equipment but limited scalability and labor intensity. Molecular assays, principally PCR and real‑time PCR, command the highest margin and represent about 35 % of the market, driven by superior sensitivity, multiplexing capability, and growing laboratory automation. Serological tests—ELISA, indirect immunofluorescence, and Western blot—hold roughly 25 % share, favored for screening large populations where antibody detection suffices, yet constrained by cross‑reactivity concerns. Antigen‑detection platforms such as enzyme‑linked immunosorbent assays for parasite proteins contribute near 10 %, offering rapid results with moderate sensitivity. Rapid diagnostic tests (RDTs) based on lateral‑flow technology complete the taxonomy with a 10 % slice, valued in point‑of‑care settings for their speed and minimal infrastructure requirements. The proportional weight of each type reflects laboratory capacity, disease endemicity, and payer reimbursement policies, collectively shaping the market’s total valuation.
